

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Jose Repolles Moliner, et al.

**Examiner:**

**Serial No.:** unassigned

**Art Unit:** unassigned

**Filed:** herewith

**Docket:** 14797

**For:** S-NITROSOTHIOLS AS AGENTS  
FOR THE TREATMENT OF  
CIRCULATORY DYSFUNCTIONS

**Dated:** July 24, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

**PRELIMINARY AMENDMENT**

Sir:

In connection with the filing of the above-described application, kindly enter the following preliminary amendments.

**AMENDMENTS**

**IN THE SPECIFICATION**

Page 1, line 3, below the title, insert as a new paragraph, the following:

---


**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

"Express Mail" Mailing Label Number: EL895322380US

Date of Deposit: July 24, 2001

I hereby certify that this Preliminary Amendment is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231.

Dated: July 24, 2001

  
\_\_\_\_\_  
Janet Grossman

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of International Application No. PCT/ES00/00019, filed on January 19, 2000.--

**IN THE CLAIMS**

Please amend Claims 3-5 and 7-9 as follows:

3. (Amended) The S-nitrosothiol derivative of claim 1 wherein said derivative is N-acetyl-2-amino-2-[4-(4-S-nitrosomercaptotetrahydropyran)] acetic acid.

4. (Amended) The S-nitrosothiol derivative of claim 1 wherein said derivative is N-acetyl-2-amino-2-[4-(4-S-nitrosomercapto-1-methylpiperidin)] acetic acid.

5. (Amended) The S-nitrosothiol derivative of claim 1 wherein said derivative is N-acetyl-2-amino-3-benzyl-3-S-nitrosomercapto-4-phenyl-butanoic acid.

7. (Amended) The S-nitrosothiol derivative of claim 1 wherein said derivative is N[N- $\gamma$ -L-glutamyl-2-amino-2-(4-(4-S-nitrosomercapto) tetrahydropyr-an))acetyl]-glycine.

8. (Amended) The S-nitrosothiol derivative of claim 1 wherein said derivative is N[N- $\gamma$ -L-glutamyl-2-amino-2-(4-(4-S-nitrosomercapto-1-methylpiperidin))acetyl]-glycine.

9. (Amended) The S-nitrosothiol derivative of claim 1 wherein said derivative is N[N- $\gamma$ -L-glutamyl-2-amino-3-benzyl-3-(S-nitrosomercapto)-4-phenylbutanoyl]-glycine.

Please delete claims 10 and 11

Please add new claims 12-18 as follows:

12. The S-nitrosothiol derivative of claim 2 wherein said derivative is N-acetyl-2-amino-2-[4-(4-S-nitrosomercaptotetrahydropyran)] acetic acid.

13. The S-nitrosothiol derivative of claim 2 wherein said derivative is N-acetyl-2-amino-2-[4-(4-S-nitrosomercapto-1-methylpiperidin)] acetic acid.

14. The S-nitrosothiol derivative of claim 2 wherein said derivative is N-acetyl-2-amino-3-benzyl-3-S-nitrosomercapto-4-phenyl-butanoic acid.

15. The S-nitrosothiol derivative of claim 1 wherein said derivative is N[N- $\gamma$ -L-glutamyl-2-amino-2-(4-(4-S-nitrosomercapto) tetrahydropyr-an))acetyl]-glycine.

16. The S-nitrosothiol derivative of claim 2 wherein said derivative is N[N- $\gamma$ -L-glutamyl-2-amino-2-(4-(4-S-nitrosomercapto-1-methylpipe-ridin))acetyl]-glycine.

17. The S-nitrosothiol derivative of claim 1 wherein said derivative is N[N- $\gamma$ -L-glutamyl-2-amino-3-benzyl-3-(S-nitrosomercapto)-4-phenylbutanoyl]-glycine.

18. A method for the treatment of dysfunctions of the circulatory system comprising providing a medicament having a platelet aggregating inhibiting-effective amount of the S-nitrosothiol derivative of claim 1.

**REMARKS**


Original claim 1-9 remain in this application. Claims 3-5 and 7-9 have been amended. Original claims 10 and 11 have been canceled. New claims 12-18 have been added.

The claims as filed in the international application have been revised to better prepare the same for U.S. prosecution. No new matter has been added in making these amendments.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is caption "**Version with markings to show changes made**".

It is respectfully requested that the above amendments be entered before an action on the merits is issued.

Respectfully submitted,



Leopold Presser  
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

EWG/vjs

**Version with markings to show changes made**

3. (Amended) The [compound of any of the claims 1 or 2,] S-nitrosothiol derivative of claim 1 wherein said derivative is N-acetyl-2-amino-2-[4-(4-S-nitrosomercaptotetrahydropyran)] acetic acid.

4. (Amended) The [compound of any of the claims 1 or 2,] S-nitrosothiol derivative of claim 1 wherein said derivative is N-acetyl-2-amino-2-[4-(4-S-nitrosomercapto-1-methylpiperi-din)] acetic acid.

5. (Amended) The [compound of any of the claims 1 or 2,] S-nitrosothiol derivative of claim 1 wherein said derivative is N-acetyl-2-amino-3-benzyl-3-S-nitrosomercapto-4-phenyl-butanoic acid.

7. (Amended) The [compound of any of claims 1 or 6,] S-nitrosothiol derivative of claim 1 wherein said derivative is N[N- $\gamma$ -L-glutamyl-2-amino-2-(4-(4-S-nitrosomercapto)tetrahydropyr-an))acetyl]-glycine.

8. (Amended) The [compound of any of claims 1 or 6,] S-nitrosothiol derivative of claim 1 wherein said derivative is N[N- $\gamma$ -L-glutamyl-2-amino-2-(4-(4-S-nitrosomercapto-1-methylpipe-ridin))acetyl]-glycine.

9. (Amended) The [compound of any of claims 1 or 6,] S-nitrosothiol derivative of  
claim 1 wherein said derivative is N[N- $\gamma$ -L-glutamyl-2-amino-3-benzyl-3-(S-  
nitrosomercapto)-4-phenylbutanoyl]-glycine.